Phase 4
N=155
Adductor Canal Block Versus Periarticular Bupivicaine Injection in Total Knee Arthroplasty
Osteoarthritis
Bottom Line
View on ClinicalTrials.gov: NCT02777749 ↗Enrolled (actual)
155
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcome: Primary: Change in VAS Pain Scores — 3.0; 3.0; 2.7; 3.9 scores on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Bupivacaine (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Columbia University
- Primary completion
- Sep 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in VAS Pain Scores |
3.0; 3.0; 2.7; 3.9; 3.8; 3.0 | — |
| SECONDARY Change in Activity Level |
26; 68; 65; 124; 120; 139 | — |
| SECONDARY Opioid Consumption |
131; 100; 98; 33; 31; 35 | — |
| SECONDARY Range of Knee Flexion |
99; 104; 101 | — |
| SECONDARY Length of Hospital Stay |
2.9; 2.5; 2.5 | — |
Summary
The objective of the study is to compare the efficacy of adductor canal blocks versus periarticular bupivacaine injections for pain management in total knee arthroplasty. This randomized clinical trial will compare outcomes between adductor canal blocks, periarticular bupivacaine injections, and periarticular liposomal bupivacaine injections. Results from this study will help determine the most appropriate perioperative pain management strategy for patients undergoing a total knee arthroplasty.
Eligibility Criteria
Inclusion Criteria
- Patients undergoing an unilateral primary total knee arthroplasty under the care of the two senior arthroplasty surgeons.
Exclusion Criteria
- Allergy to bupivicaine or liposomal bupivicaine.
Data sourced from ClinicalTrials.gov (NCT02777749). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.